Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28366319 | 0.98 | ALDH1A1 (0.60) | ALDH1A1HRH3SMN1; SMN2POLBHTT | |
| SCHEMBL16054572 | 0.84 | L3MBTL3 (0.58) | ALDH1A1HRH3SMN1; SMN2POLBHTT | |
| SCHEMBL6733401 | 0.84 | ALDH1A1 (0.58) | ALDH1A1HRH3SMN1; SMN2POLBHTT | |
| SCHEMBL5722022 | 0.84 | ALDH1A1 (0.58) | ALDH1A1HRH3SMN1; SMN2POLBHTT | |
| SCHEMBL12239191 | 0.84 | ALDH1A1 (0.72) | ALDH1A1HRH3SMN1; SMN2POLBHTT | |
| SCHEMBL28743480 | 0.84 | ALDH1A1 (0.58) | ALDH1A1HRH3SMN1; SMN2POLBHTT | |
| SCHEMBL6735828 | 0.84 | POLB (0.72) | ALDH1A1HRH3SMN1; SMN2POLBHTT | |
| SCHEMBL5519966 | 0.81 | ALDH1A1 (0.69) | ALDH1A1HRH3SMN1; SMN2POLBHTT | |
| SCHEMBL9612032 | 0.81 | POLB (0.69) | ALDH1A1HRH3SMN1; SMN2POLBHTT | |
| SCHEMBL16054965 | 0.81 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2POLBKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105008348-B | Pyrazolylbenzo [ D ] imidazole derivatives | 赛隆制药股份公司 | 2018-07-10 | — | — | CN | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| EP-2809668-B1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-12 | — | — | EP | disclosed |
| EP-2970210-B1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | Celon Pharma Sa (PL) | 2017-01-04 | — | — | EP | disclosed |
| EP-2970210-B1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | Celon Pharma Sa (PL) | 2017-01-04 | — | — | EP | disclosed |
| US-9266876-B2 | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20160039794-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2016-02-11 | — | — | US | disclosed |
| US-20160039794-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2016-02-11 | — | — | US | disclosed |
| WO-2014141015-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014141015-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2014-09-18 | — | — | WO | disclosed |
| US-8778936-B2 | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| CN-101857589-B | Pyrazol-benzimidazoles derivative and application thereof | UNIV SOUTHEAST | 2013-12-18 | — | — | CN | disclosed |
| US-8399442-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-07-26 | — | — | US | disclosed |
| US-8110573-B2 | Enzyme inhibitors; Cyclin-Dependent Kinases (CDK), Glycogen Synthase Kinases (GSK); -cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea salt for example; anticancer agents | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-07 | — | — | US | disclosed |
| CN-101857589-A | Pyrazol-benzimidazoles derivative and application thereof | UNIV SOUTHEAST | 2010-10-13 | — | — | CN | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004232-A1 | Pharmaceutical Compounds | ERBB3, ABL1, RET | ALDH1A1 3042/4885HRH3 687/4885SMN1; SMN2 3461/4885 |
| US-20160039794-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | NR0B2, NR2C2, NR4A3 | ALDH1A1 2014/4885HRH3 246/4885SMN1; SMN2 3327/4885 |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK3, CDK1, AURKA | ALDH1A1 3717/4885HRH3 2160/4885SMN1; SMN2 2569/4885 |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | CDK3, CDK1, AURKA | ALDH1A1 3717/4885HRH3 2160/4885SMN1; SMN2 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.